New Approach Improves Breast Cancer Survival

This is a UK news story, published by ScienceDaily, that relates primarily to Abraham news.

UK news

For more UK news, you can click here:

more UK news

Abraham news

For more Abraham news, you can click here:

more Abraham news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

ScienceDaily news

For more news from ScienceDaily, you can click here:

more news from ScienceDaily

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

aggressive breast cancers

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest breast cancers news, breast cancer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

stage breast cancer

ScienceDaily

•

Health

New approach to treating aggressive breast cancers shows significant improvement in survival

Summary

Nutrition label

77% Informative

New treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers.

100% of patients survived the critical three-year period post-surgery.

Cancer patients treated with chemotherapy followed by a targeted cancer drug before surgery.

Discovery could become the most effective treatment to date for early-stage breast cancer.

Professor Abraham and team are now planning the next phase of the research, which will look to replicate the results in a larger study.

The Partner trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge , funded by Cancer Research UK and AstraZeneca , and supported by the NIHR Cambridge Biomedical Research Centre .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful